Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Construction in Progress Convertible Debt Current Assets Current Deferred Revenue Current Leases Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Prepaid Assets Property, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw Materials Receivables Receivables - Net Receivables - Other Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Treasury Shares Work In Process

Cash Flow Statement

Daily Values

Growth Metrics

Dexcom (DXCM) Notes Payables (2022 - 2025)

Dexcom has reported Notes Payables over the past 4 years, most recently at $1.2 billion for Q3 2025.

Quarterly Notes Payables changed N/A to $1.2 billion in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.2 billion through Sep 2025, changed N/A year-over-year, with the annual reading at $1.2 billion for FY2024, N/A changed from the prior year.
Notes Payables was $1.2 billion for Q3 2025 at Dexcom, roughly flat from $1.2 billion in the prior quarter.
Over five years, Notes Payables peaked at $1.2 billion in Q3 2025 and troughed at $124.2 million in Q3 2023.
The 4-year median for Notes Payables is $989.1 million (2023), against an average of $908.3 million.